Tag Archives: Another pharma substitution case fails false advertising

Another pharma substitution case fails

Sebela Pharmaceuticals Inc. v. TruPharma, LLC, 2021 WL 4316750, No. 1:20-cv-1677-SB (D. Del. Sept. 8, 2021) When a false advertising case starts this way, you can guess how it will end: “Market competition is good. Competitors are free to copy … Continue reading

Posted in Uncategorized | Tagged | Leave a comment